Author Archives: admin


Bluebird Bios first gene therapy for rare blood disease wins FDA approval – The Boston Globe

Zynteglo could change that by providing a healthy copy of the essential beta-globin gene to blood stem cells, allowing their bodies to make healthy blood cells and eliminate the need for regular transfusions. In clinical trials, about 90 percent of patients who got the one-time therapy no longer needed transfusions to treat their disease.

Dr. David A. Williams, chief of hematology/oncology at Boston Childrens Hospital, was impressed with the effectiveness of the therapy. This is clearly very clinically meaningful for the patients, he said.

Before Zynteglos approval, stem cell transplants were the only potentially curative options for people with beta thalassemia, but many people with the condition are unable to find a genetically-matched donor. Doctors who treat people with the condition were excited by the approval of Zynteglo.

This is really huge. The idea that now you have the option of a curative therapy for all patients is enormous, said Dr. Sujit Sheth, chief of the division of pediatric hematology/oncology at Weill Cornell Medicine.

Sheth noted that stem cell transplants carry the risk of immune rejection, which can be deadly. You have a far lower risk of complications from getting your own cells back than if youre getting it from someone else, he said.

Bluebird estimates that there are as many as 1,500 people with transfusion-dependent beta thalassemia in the United States. Thomas Klima, the firms chief commercial officer, told the Globe that as many as 850 of them may qualify for Zynteglo.

The firm expects about one-third of those patients to be pretty eager to get therapy, Klima added. Another third may need more information and time to think it over, and the final third may consider their current transfusion treatments fine.

Despite the relatively modest numbers of patients who may get the therapy, the approval is a major win for Bluebird, which has faced a series of troubles over the past few years that brought its stock falling about 98 percent from its peak in 2018. The firm said it would lay off 30 percent of its employees in April and warned investors it only had enough cash to last until the first half of 2023.

Over the last year we faced so many challenges, Klima said. But the group thats here now and the group thats getting ready to launch our gene therapies couldnt be more thrilled.

The therapy is made from a patients own blood stem cells collected during a hospital visit and shipped to the contract manufacturing firm Lonza, just south of Houston, TX. Once there, scientists will treat the cells with Bluebirds gene therapy, made from a lentivirus that shuttles the beta-globin gene into the cells.

After a quality check, cells are shipped back to the hospital. Before getting the altered cells infused, a patient must undergo chemotherapy to clear out space in their bone marrow for the new cells to engraft. Once they take hold, they will make new healthy red blood cells for years, potentially indefinitely.

Craig Butler, national executive director of the Cooleys Anemia Foundation a nonprofit patient organization for thalassemia is excited for people to have an alternative to time-consuming transfusions.

Its usually a full day process for someone, which means that theyre missing a day of work or a day of school, he said. The approval of Zynteglo means that they will no longer have to be bound to transfusions for the rest of their lives.

Wanda Sihanath, 26, was one of the first people to get the therapy in a clinical trial in 2014. She hasnt needed a transfusion in over eight years. It feels like really great not to be tethered to hospital and having to check in at least once a month, she said.

Sihanath, who lives in San Jose, was excited to hear that Zynteglo is approved. I am super stoked, she said, and is hopeful that the therapy will help untether people from regular hospital visits.

But the chemotherapy Sihanath got to prepare her body for the gene therapy may have affected her fertility, and she wishes she would have sought a little more counseling about getting the procedure at a young age. Doctors say that some young people may wish to hold off on getting the therapy.

The therapy will only be offered at a small number of centers across the United States, including at Boston Childrens Hospital.

Colleen Dansereau, the hospitals director of clinical operations of the gene therapy program, anticipates that the hospital will be ready to start the treatment procedure for a patient by September. But she anticipates it could take longer for Bluebird to get ready and for insurers to guarantee payment for the therapy.

Boston Childrens regularly provides transfusions for about 45 people with the condition, plus additional patients referred from other centers, Dansereau said.

The hospital may end up treating additional patients with beta thalassemia from other parts of the world where the disease is more prevalent, including the Middle East and Southeast Asia, Dansereau added. We anticipate that we could have an increase in our international services for this particular product.

Zynteglo is the third gene therapy approved by the FDA. The Roche gene therapy Luxturna, which treats a genetic eye disease, was approved in 2017 with a price tag of $850,000. The Novartis gene therapy Zolgensma, which treats spinal muscular atrophy, was approved in 2019 with a cost of $2.1 million. The FDA could approve a fourth gene therapy, also made by Bluebird, in September.

Ryan Cross can be reached at ryan.cross@globe.com. Follow him on Twitter @RLCscienceboss.

Continued here:
Bluebird Bios first gene therapy for rare blood disease wins FDA approval - The Boston Globe

Molecular Map Reveals Insights Into the Genetic Drivers of CLL – The ASCO Post

By The ASCO Post Staff Posted: 8/16/2022 2:43:00 PM Last Updated: 8/16/2022 3:15:33 PM

A newly constructed map of the landscape of genetic changes in chronic lymphocytic leukemia (CLL) may provide a better understanding of this complex malignancy that could lead to more accurate prognoses for patients, improved diagnostics, and novel treatments. These research findings were published by Knisbacher et al in Nature Genetics, and the study was conducted by an international collaboration of investigators, including teams from the Mass General Cancer Center, the Dana-Farber Cancer Institute, and the Broad Institute of MIT and Harvard.

CLL exists as either a slowly or rapidly growing cancer and has been linked to certain genetic mutations, but it has yet to be fully characterized. Previous analyses have provided only fragments of a CLL map, each focusing on particular types of patients or limited data. To provide a more thorough understanding of the biological underpinnings of CLL and its molecular subtypes, scientists set out to construct a map from the largest CLL data set to date. To build the CLL map, the team analyzed variations in genetic sequences, gene-expression patterns, and chemical modifications to DNAor genomic, transcriptomic, and epigenomic datafrom 1,148 patients.

Such a CLL map could eventually be leveraged in the clinic, wherein the genomic features of new patients can be compared with the treatments and outcomes of patients with similar genetic profiles, said co-senior and co-corresponding author Catherine Wu, MD, Chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. This profiling could potentially help more accurately tailor prognosis and treatment of a new patient based on their particular molecular features, getting closer to precision medicine.

Key Findings

The scientists identified 202 genes109 of which were novelthat when mutated, could potentially drive CLL, and they refined the characterization of subtypes of CLL with distinct genomic characteristics and prognoses. Beyond genetic sequences, the expression patterns of certain genes further subcategorized CLL and provided valuable prognostic information.

Our study has revealed that the genetic and biologic landscape of CLL is more complex than previously appreciated, said co-senior and co-corresponding author Gad Getz, PhD, Director of Bioinformatics at the Mass General Cancer Center and Director of the Cancer Genome Computational Analysis group at the Broad Institute. Patients clinical outcomes were associated with a combination of genomic, transcriptomic, and epigenomic featuresintegrating these data could predict a patients likelihood of experiencing remission vs developing more advanced cancer.

We are releasing a CLL map portal that is based on the CLL map and will be an interactive website for translational researchers to use as a resource for further investigationsuch as learning more about the different drivers and subtypes of CLL, said Dr. Getz.

Disclosure: This work was supported by the National Institutes of Health and the Broad/IBM Cancer Resistance Research Project. For full disclosures of the study authors, visit nature.com.

View post:
Molecular Map Reveals Insights Into the Genetic Drivers of CLL - The ASCO Post

MESO NUMISMATICS, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) – Marketscreener.com

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, cybersecurity, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further, information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

Since the acquisition of Global Stem Cell Group in August last year, our focus has been mainly dedicated to its operations serving the markets in the regenerative medicine industry. We still have numismatics operation, but the overall plan for the company is too move from the sale of coins, paper currency, bullion and medals into what we believe is a more lucrative opportunity for our company.

We work with doctors and their staff to provide products, solutions, equipment, services, and training to help them be successful in the application of Stem Cell Therapies. Our team combines solutions from extensive clinical research with the manufacturing and commercialization of viable cell therapy and immune support related products that we believe will change the course of traditional medicine around the world forever. Our strategy allows us the ability to create immediate revenue streams through product sales, distribution, and clinical applications, driven by our extensive education platform. Our revenue comes directly from the training and the seminars, from the resale of these kits, products, and equipment, services, and from the reoccurring application of our process using the kits and solutions we provide.

Global Stem Cells Group is a leader in the Stem Cell and Regenerative Medicine fields, covering clinical research, patient applications, along with physician training through our state-of-the-art global network of companies. The Company's mission is to enable physicians to make the benefits of stem cell medicine a reality for patients around the world. They have been educating doctors on the science and application of cell-based therapeutics for the past 10 years. Our professional trademarked association "ISCCA" INTERNATIONAL SOCIETY FOR STEM CELL APPLICATION is a global network of medical professionals that leverages these multinational relationships to build best practices and further our mission.

The Company envisions the ability to improve "health-span" through the discovery and developments of new cellular therapy products, and cutting-edge technology.

Global Stem Cells Group, as almost everyone else in the world, was severely affected by the covid 19 pandemic. As we look to recover in 2022, we are integrating every aspect of the regenerative medicine industry. During 2022, we plan to add manufacturing and commercialization of viable cell therapy and immune support related products that we believe will change the course of traditional medicine around the world forever.

We believe this strategy will allow us the ability to increase our current revenues and create immediate revenue streams through product sales, distribution, and clinical applications, driven by our extensive education platform here are our main projects and revenue generators for 2022 and beyond.

Results of Operations for the Three Months Ended June 30, 2022 and 2021.

Revenue increased by 1,831% in the amount of $288,752 for the three months ended June 30, 2022, compared to the same period in 2021. The key reason for the increase in revenue was a result of the acquisition of Global Stem Cells Group, Inc. on August 18, 2021. Revenue from viable cell therapy and immune support related products along with physician training was $297,521 and a decrease in sale of coins, metals and paper money of $8,769 for the three months ended June 30, 2022, compared to the same period in 2021.

Listed below are the revenues, cost of revenues and gross profits by Company for the three months ended June 30, 2022:

We expect to increase our revenues in future quarters from our operations associated with Global Stem Cells with less expected revenues in future quarters associated with our numismatic operations.

Operating expenses increased by 99% in the amount of $255,634 for the three months ended June 30, 2022, compared to the same period in 2021. Listed below are the major changes to operating expenses:

Advertising and marketing fees increased by $80,817 for the three months ended June 30, 2022, compared to the same period in 2021, primarily due to the acquisition of Global Stem Cells Group, Inc. on August 18, 2021.

Depreciation and amortization increased by $35,125 for the three months ended June 30, 2022, compared to the same period in 2021, primarily due to completion of Cancun lab in May 2022.

General and administrative expense increase by $125,359 for the three months ended June 30, 2022, compared to the same period in 2021, primarily due to the acquisition of Global Stem Cells Group, Inc. on August 18, 2021.

Other expense increased by $456,085 for the three months ended June 30, 2022, compared to the same period in 2021, primarily as a result of the increase in interest on promissory notes. During the six months ended June 30, 2021, we received $11,400,000 in proceeds received from the issuance of promissory notes. We expect other expense to increase in future quarters as a result of the interest on the new debt.

We recorded a net loss of $1,493,065 for the three months ended June 30, 2022, as compared with a net loss of $926,077 for the same in 2021.

Results of Operations for the Six Months Ended June 30, 2022 and 2021.

Revenue increased by 2,941% in the amount of $594,387 for the six months ended June 30, 2022, compared to the same period in 2021. The key reason for the increase in revenue was a result of the acquisition of Global Stem Cells Group, Inc. on August 18, 2021. Revenue from viable cell therapy and immune support related products along with physician training was $596,270 and a decrease in sale of coins, metals and paper money of $1,883 for the six months ended June 30, 2022, compared to the same period in 2021.

Listed below are the revenues, cost of revenues and gross profits by Company for the six months ended June 30, 2022:

We expect to increase our revenues in future quarters from our operations associated with Global Stem Cells with less expected revenues in future quarters associated with our numismatic operations.

Operating expenses increased by 190% in the amount of $761,900 for the six months ended June 30, 2022, compared to the same period in 2021. Listed below are the major changes to operating expenses:

Advertising and marketing fees increased by $135,194 for the six months ended June 30, 2022, compared to the same period in 2021, primarily due to the acquisition of Global Stem Cells Group, Inc. on August 18, 2021.

Professional fees increased by $262,824 for the six months ended June 30, 2022, compared to the same period in 2021, primarily due to audit and accounting expenses.

Depreciation and amortization increased by $61,902 for the six months ended June 30, 2022, compared to the same period in 2021, primarily due to completion of Cancun lab in May 2022.

General and administrative expense increase by $216,667 for the six months ended June 30, 2022, compared to the same period in 2021, primarily due to the acquisition of Global Stem Cells Group, Inc. on August 18, 2021.

Other expense increased by $1,271,308 for the six months ended June 30, 2022, compared to the same period in 2021, primarily as a result of the increase in interest on promissory notes. During the six months ended June 30, 2021, we received $11,400,000 in proceeds received from the issuance of promissory notes. We expect other expense to increase in future quarters as a result of the interest on the new debt.

We recorded a net loss of $3,170,029 for the six months ended June 30, 2022, as compared with a net loss of $1,398,384 for the same in 2021.

Liquidity and Capital Resources

Since inception, the Company has financed its operations through private placements and convertible notes. The following is a summary of the cash and cash equivalents as of June 30, 2022 and December 31, 2021.

Edgar Online, source Glimpses

Visit link:
MESO NUMISMATICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com

Illinois Innovation Network honors innovators from across state – University of Illinois

The Illinois Innovation Network (IIN) announced recipients of its second-annual innovation awards Wednesday at the Illinois State Fairs Tech Prairie STEAM Expo, recognizing individuals from the IINs 15 hubs who have made key advances in research, technology commercialization and education.

The awards were presented to faculty, staff or scientists from IIN hubs in four of the IINs key subject areas: computing and data, environment and water, food and agriculture, and health and wellness. The IIN also presented awards for an open category of innovation and to a student innovator from IIN hubs.

It is our honor to celebrate these innovators and their discoveries, said Jay Walsh, vice president for economic development and innovation for the University of Illinois System, which coordinates the IIN. They all are shining examples of the fantastic research and discovery happening across our state.

Innovators were honored for developments in using numerous data streams to provide in-depth forecasting systems for agricultural ecosystems, the discovery and utilization of microbial biomes to produce new materials from organic waste, creating a new method to manufacture biodegradable plastic from agricultural biomass and food waste, and a new program that gives children the opportunity to gain real-life space exploration experience.

These innovators are an example of one of the things I love most about our state: we have brilliant people coming up with solutions to some of the worlds most difficult challenges, said Bruce Sommer, director of economic development and innovation at the University of Illinois Springfield, whose office facilitated the awards program. I am encouraged by the diversity of our recipients and the incredible work that they are doing.

IIN Innovation Award recipients Computing & Data Category Kaiyu Guan, Blue Waters associate professor in ecohydrology and remote sensing, University of Illinois Urbana-Champaign Dr. Guan developed the technology to observe and measure land and water resources for every farm on the planet, which powers his startup company Habiterre. Habiterre integrates data streams from satellites, airplanes, automobiles and ground sensor networks to create a comprehensive view of farmland. Those data streams are processed with the companys fusion algorithms, which eliminate gaps in the data and remove the effects of clouds, and have been verified with actual ground truth information, creating a quantitative analysis of individual fields at a 30-meter (100-foot) resolution and at a daily frequency, recording the past 20+ years. Then they apply scientific models and proprietary algorithms to evaluate crop growth conditions, water use, biochemical status, and management practices. Starting with a well-established scientific model for simulating entire agriculture ecosystems, Habiterre added proprietary improvements that incorporate hundreds of variables above and below ground, then it constrained the model with actual observations, create a reliable, realistic and holistic view of each farm. This effort has created the most advanced model for crop growth, carbon cycles, and nutrient dynamics. Using AI and advanced mathematical tools to combine the data and model, we have created the first real forecasting capabilities for agro-ecosystems. Habiterre can directly see how different components of carbon, water, and nutrients change during the growth season and how they are impacted by farming practices. Additionally, the company can create simulations that make it possible to predict the outcomes of various changes, from switching crop varieties and management practices, to assessing the impacts of climate change. With the aid of supercomputers and cloud computing, they can process millions of farm-level simulations simultaneously, allowing us to achieve field-level accuracy over large geographic areas.

Environment & Water Category Scott Hamilton-Brehm, associate professor in biological sciences, Southern Illinois University Carbondale Dr. Hamilton-Brehm is an innovator in the discovery and utilization of geothermal and subsurface microbial biomes to perform green remediation and recovery of organic waste to produce new materials and to produce value-added materials and food. Hamilton-Brehm holds two patents, led the student team that received funding as one of the finalists in the Carbon Removal XPRIZE competition, and was part of the team selected for funding through the NASA Deep Space Food Challenge. Dr. Hamilton-Brehm also led the efforts by SIU to produce for the State of Illinois over 100,000 vials of Viral Transport Medium (VTM) during the early days of the COVID-19 pandemic. The Carbon Removal XPRIZE award focused on the innovative use of Oxidative Hydrothermal Dissolution (OHD) to convert captured carbon, in the form of almost any plant-based waste biomass, into a water-soluble liquid. The resulting liquid can then be pumped into natural or man-made geologic recesses where microbes will eat the waste, thereby sequestering the carbon contained within the waste. The advantage of this approach over air-based carbon capture is dramatically revealed when one recognizes that one pound of raw plant matter contains about the same amount of carbon as one million liters of air. Hamilton-Brehm and his team were selected as one of the top 60 teams worldwide for the XPRIZE. More recently, Hamilton-Brehm and his team played a crucial role in obtaining funding from NASA through the Deep Space Food Challenge program to develop their next-generation food production system called Bites, which will utilize plastic and biomass waste as the carbon source for food generation.

Food & Agriculture Category Lahiru Jayakody, assistant professor in microbiology, Southern Illinois University Carbondale Dr. Jayakody is a young innovator in synthetic microbiology and green chemistry and holds or has applications for seven patents. His patents on engineering robust microbial cell factories apply to developing multiple technologies, including valorization of unconventional feedstock such as industrial-wastewater streams and waste plastic. He developed a novel thermo-bio-catalytic hybrid process to valorize untapped waste carbon in the agricultural biomass, i.e., high-toxic aldehydes and aromatics, industrial food waste, and waste plastic. His innovative approach merged engineered microbial-based biofunneling and biofunctionalization of organic substrates with Dr. Ken Anderson's (2021 IIN Innovation Award) Oxidative Hydrothermal Dissolution technology (OHD), to produce advanced platform chemicals to replace incumbent petrochemicals and microbial-based food ingredients for next-generation food production. Jayakody partnered with one of the world's leading green tea manufacturers, Ito En Japan, to develop and commercialize technology to manufacture novel biodegradable plastic from waste tea, coffee, and postconsumer polyethylene terephthalate (PET) bottles. The generated chemicals will be used to make advanced PET alternatives and smart food packaging materials. He also leads the team "Bites," which has invented a next-generation food production system using this technology. His innovative synthetic microbial-based process converts waste plastic into edible, 3D printed, customized, nutritious food for astronauts. His team was one of 18 winners of the Phase I NASA Deep Space Food Challenge and the only Illinois-based team.

Health & Wellness Category Mohammad Islam, research assistant professor in chemistry, University of Illinois Chicago Dr. Islam has recently engineered a cell-based method of preventing infection from the SARS-CoV-2 virus. Spike protein (S) of SARS-CoV-2 uses human receptor containing angiotensin-converting enzyme 2 (ACE2) cells to initiate viral entry into the body. By preventing the receptor binding domain (RBD) of S protein from binding with ACE2 cells, SARS-CoV-2 can be prevented from infecting the human body. Dr. Islam developed an ACE2 decoy receptor that binds with the RBD of SARS-CoV-2 spike protein with low nanomolar affinity and 10-fold affinity enhancement over the wildtype. Dr. Islam used computational mutagenesis and molecular dynamics simulations to design the soluble decoy ACE2, which is known as ACE2-FFWF. This research was published in the Journal of Chemical Information and Modelling, (J. Chem. Inf. Model. 61, 46564669) where Dr. Islam acted as the principal investigator and the corresponding author of the paper. Dr. Islams research develops and advances a new class of soluble sACE2 that can act as potential therapeutics against variants of concern, namely omicron, alpha, beta, delta, delta plus, and gamma.

Open Category Keith Jacobs, statewide 4-H STEM specialist, University of Illinois Extension Keith Jacobs is uniquely contributing to the recruitment, diversification and mentoring of the next generation workforce in computing and STEM. Jacobs designed a new program called 4-H in Space that gives middle and high school youth the opportunity to gain real-life experience in space exploration by building, programming, and launching real satellites into orbit. The students gain deep experience in subjects like coding, mechanical engineering and astronomy, all of which help hone their STEM skills. Jacobs expects to reach some 2,000 young people in this first year of the program, with a goal of reaching 10,000 young people by 2025. Additionally, Jacobs developed partnerships with the Laboratory for Advanced Space Systems in Illinois (LASSI), and the International Space Station national Laboratories (ISSNL) to create unique hands-on learning opportunities for youth in the program. A select group of youth the Illinois Mission Command team traveled to the Kennedy Space Center in Florida in July 2022, where they designed an experiment to be launched and tested on the International Space Station. In collaboration with the LASSI group in the University of Illinois Urbana-Champaigns Aerospace Engineering Department, Mission Control youth will code and launch a cube satellite in 2023. Youth will then monitor and analyze data received from the programmed sensors in space. The youth in Mission Control reflect the racial and ethnic diversity of Illinois, and reflect Jacobs commitment to inspiring under-represented youth to pursue STEM careers. Jacobs innovative program design is already being scaled to other states through the network of land-grant universities. To date, he has trained and mentored 4-H staff in three other states. In 2023, his curriculum 4-H in Space will be made available, with the potential reach the 7 million youth in 4-H across the country.

Student Category Pierre Paul, We Hear You, Distillery Labs Paul and his team have developed We Hear You, an AI-based sign language translator as well as a personalized automatic door opener fob for persons with disabilities that are accommodated under the Americans with Disabilities Act. Currently, the ADA guidelines only provide guidance based on the minimum standards and requirements that have to be met. We Hear You's mission is to improve the quality of life for persons with disabilities, and they are actively seeking to create solutions that proactively resolve the challenges that they continue to face even when there are accessible pathways throughout their daily journeys. Pierre and his team have validated the problem they're solving in providing innovative solutions that solve accessibility issues. They have won a number of competitions including the Social Innovation Challenge, and the Big Idea Competition while at Bradley University. Additionally, they have been incubated at Bravelaunch, gBETA Distillery Labs, and most recently at UIUCs iVenture Accelerator.

Excerpt from:
Illinois Innovation Network honors innovators from across state - University of Illinois

Kraig Biocraft Laboratories Expands Operational Footprint in Vietnam

ANN ARBOR, Mich., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces that the Company has now been granted a business license to begin operations in Lam Dong Province.

Continued here:
Kraig Biocraft Laboratories Expands Operational Footprint in Vietnam

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a…

Nes-Ziona, Israel, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Israeli Ministry of Health (MOH) authorized the initiation of a company-sponsored Phase I/II clinical trial designed to evaluate the safety, tolerability and preliminary efficacy of Allocetra™ alone, and in combination with a PD1 checkpoint inhibitor, in patients with advanced solid tumors.

More here:
Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a...

Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors

CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it has appointed Michael Vasconcelles, M.D. to its board of directors. Dr. Vasconcelles will also serve on the company’s R&D Committee and Nominating and Corporate Governance Committee.

More here:
Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors

Oncotelic Participating at Biotechgate Digital Partnering

AGOURA HILLS, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced that the Company will be participating at Biotechgate Digital Partnering – a business development & licensing event - Aug 29 - Sep 2, 2022. An updated investor slide deck will be available at our website after the event.

Continue reading here:
Oncotelic Participating at Biotechgate Digital Partnering

Blue Water Vaccines Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate

CINCINNATI, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that the Company plans to explore the potential to develop a novel monkeypox vaccine using its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform.

More here:
Blue Water Vaccines Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate

Scilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC to Expand Commercialization…

PALO ALTO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, today announced the signing of a Product Distribution Agreement (“Agreement”) for certain designated territories with CH Trading Group LLC (“CH Trading”), an international import, export and trading company focused on the Middle East and North Africa (MENA) Region and other markets, to distribute Scilex’s lead non-opioid commercial pain management product, ZTlido®. Scilex is a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”).

Go here to read the rest:
Scilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC to Expand Commercialization...